In a report released today, Ryan Deschner from Raymond James maintained a Buy rating on ARS Pharmaceuticals (SPRY – Research Report), with a price target of $32.00. The company’s shares opened today at $12.16.
According to TipRanks, Deschner is an analyst with an average return of -2.4% and a 47.62% success rate. Deschner covers the Healthcare sector, focusing on stocks such as ARS Pharmaceuticals, Ardelyx, and Liquidia Technologies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ARS Pharmaceuticals with a $30.67 average price target, representing a 152.22% upside. In a report released today, Scotiabank also maintained a Buy rating on the stock with a $30.00 price target.
The company has a one-year high of $18.51 and a one-year low of $7.55. Currently, ARS Pharmaceuticals has an average volume of 1.7M.
Read More on SPRY:
- ARS Pharmaceuticals Reports Strong Q1 2025 Performance
- Morning Movers: Sony and Dynatrace jump following earnings
- ARS Pharmaceuticals reports Q1 EPS (35c), consensus (36c)
- ARS Pharmaceuticals’ neffy 1mg now available across U.S.
- ARS Pharmaceuticals: Strategic Partnership and Market Expansion Drive Buy Rating
